Raising the Bar: Aiming for Clinical Remission in Severe Asthma

Webinar recorded Oct. 26, 2023
Sponsored by GSK

Approximately 5%-10% of all asthma patients in the US have severe asthma. Patients with severe asthma who are uncontrolled are at risk for oral corticosteroid dependence, exacerbations, and progressive loss of lung function. Clinical remission has been proposed as a new target for patients with severe asthma with the goal of slowing or stopping disease progression. The concept of clinical remission takes a more holistic view of the disease in that it includes achieving a combination of parameters and not a single endpoint such as symptom relief. Similar to the evolution observed with other inflammatory disease states, such as rheumatoid arthritis, availability of new therapies allows for the consideration as to whether clinical remission is an achievable treatment target in severe asthma. This program will provide disease education for population-based decision makers to inform on the concept of clinical remission and next steps in elevating clinical remission as a goal for asthma.

Learning Objectives:

• Describe the evolution of clinical remission as a target in other chronic inflammatory diseases.
• Share perspective of the value of achieving clinical remission, for patients with severe asthma, including improvements in daily life and long-term outcomes.
• Define components of clinical remission for severe asthma and trajectory of this goal.

Speaker:

John Oppenheimer, MD
Director of Clinical Research, Pulmonary and Allergy Associates
Clinical Professor of Medicine, UMDNJ-Rutgers

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by: